Among all missense mutations of BRCA2 in MSH2/MLH1-mutant MSI-H CRCs, 9 were previously reported in breast, ovarian, pancreatic and uterine cancers and 14 variants involved the same reported sites in breast cancer but with different amino acid substitutions in CRC. This evidence concerns the gene BRCA2 and colorectal carcinoma.